Accès gratuit
Numéro
Med Sci (Paris)
Volume 29, Numéro 12, Décembre 2013
Page(s) 1092 - 1094
Section Nouvelles
DOI http://dx.doi.org/10.1051/medsci/20132912010
Publié en ligne 20 décembre 2013
  1. Baysal BE, Ferrell RE, Willett-Brozick JE, et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 2000 ; 287 : 848–851. [CrossRef] [PubMed]
  2. Favier J, Gimenez-Roqueplo AP. La génétique des paragangliomes et des phéochromocytomes. Med Sci (Paris) 2012 ; 28 : 625–632. [CrossRef] [EDP Sciences] [PubMed]
  3. Gimenez-Roqueplo AP, Dahia PL, Robledo M. An update on the genetics of paraganglioma, pheochromocytoma, and associated hereditary syndromes. Horm Metab Res 2012 ; 44 : 328–333. [CrossRef] [PubMed]
  4. Amar L, Baudin E, Burnichon N, et al. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J Clin Endocrinol Metab 2007 ; 92 : 3822–3828. [CrossRef] [PubMed]
  5. Emile JF. Les tumeurs stromales gastro-intestinales (GIST). Med Sci (Paris) 2013 ; 29 : 630–633. [CrossRef] [EDP Sciences] [PubMed]
  6. Letouze E, Martinelli C, Loriot C, et al. SDH Mutations establish a hypermethylator phenotype in paraganglioma. Cancer Cell 2013 ; 23 : 739–752. [CrossRef] [PubMed]
  7. Eisenhofer G, Pacak K, Huynh TT, et al. Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma. Endocr Relat Cancer 2011 ; 18 : 97–111. [CrossRef] [PubMed]
  8. Loriot C, Burnichon N, Gadessaud N, et al. Epithelial to mesenchymal transition is activated in metastatic pheochromocytomas and paragangliomas caused by SDHB gene mutations. J Clin Endocrinol Metab 2012 ; 97 : E954–E962. [CrossRef] [PubMed]
  9. Pastor WA, Aravind L, Rao A. TETonic shift : biological roles of TET proteins in DNA demethylation and transcription. Nat Rev Mol Cell Biol 2013 ; 14 : 341–356. [CrossRef] [PubMed]
  10. Turcan S, Rohle D, Goenka A, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012 ; 483 : 479–483. [CrossRef] [PubMed]
  11. Xu W, Yang H, Liu Y, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 2011 ; 19 : 17–30. [CrossRef] [PubMed]
  12. Xiao M, Yang H, Xu W, et al. Inhibition of alpha-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. Genes Dev 2012 ; 26 : 1326–1338. [CrossRef] [PubMed]
  13. Yang M, Soga T, Pollard PJ. Oncometabolites : linking altered metabolism with cancer. J Clin Invest 2013 ; 123 : 3652–3658. [CrossRef] [PubMed]